Nitrostyrene derivatives act as RXRα Ligands to inhibit TNFα activation of NF-κB

Cancer Research

Volumn 75, Issue 10, 2015, Pages 2049-2060

  Zeng, Zhiping ^a   Sun, Zhe ^a   Huang, Mingfeng ^a   Zhang, Weidong ^a   Liu, Jie ^a   Chen, Liqun ^a   Chen, Fan ^a   Zhou, Yuqi ^a   Lin, Jiacheng ^a   Huang, Fengyu ^a   Xu, Lin ^a   Zhuang, Zixing ^a   Guo, Shangjie ^a   Alitongbieke, Gulimiran ^a   Xie, Guobin ^a   Xu, Yang ^a   Lin, Bingzhen ^b   Cao, Xihua ^b   Su, Ying ^a,b   Zhang, Xiao Kun ^a,b   Zhou, Hu ^a   more..

^a XIAMEN UNIVERSITY   (China)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITROSTYRENE DERIVATIVE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RETINOID X RECEPTOR ALPHA; RIP1 PROTEIN; STYRENE DERIVATIVE; TRANSCRIPTION FACTOR GAL4; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TYROSINE; UNCLASSIFIED DRUG; (E)-1-(2-NITROVINYL)NAPHTHALENE; (E)-9-(2-NITROVINYL)ANTHRACENE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; NAPHTHALENE DERIVATIVE; PROTEIN BINDING; TNF PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; DNA BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIGAND BINDING; MCF 7 CELL LINE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSACTIVATION; UBIQUITINATION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; ANTHRACENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; NAPHTHALENES; NF-KAPPA B; PROTEIN BINDING; RETINOID X RECEPTOR ALPHA; SIGNAL TRANSDUCTION; STYRENES; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942910045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2435     Document Type: Article

References (43)

1. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 2004;11:S126-43.
2. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007;6:811-20.
3. Huang J, Powell WC, Khodavirdi AC, Wu J, Makita T, Cardiff RD, et al. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res 2002;62:4812-9.
4. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000;407:633-6.
5. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-82.
6. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 2007; 56:1557-63.
7. Hegele RA. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:2088.
8. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-40.
9. Cao X, Liu W, Lin F, Li H, Kolluri SK, Lin B, et al. Retinoid X receptor regulates Nur77/TR3-dependent apoptosis [corrected] by modulating its nuclear export and mitochondrial targeting. Mol Cell Biol 2004;24: 9705-25.
10. Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007;109:3741-4.
11. Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim Biophys Acta 2012;1821:21-56.
12. Altucci L, Leibowitz MD, Ogilvie KM, deLera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810.
13. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 2000;19:2592-601.
14. Chen L, Wang ZG, Aleshin AE, Chen F, Chen J, Jiang F, et al. Sulindac-derived RXRalpha modulators inhibit cancer cell growth by binding to a novel site. Chem Biol 2014;21:596-607.
15. Wang GH, Jiang FQ, Duan YH, Zeng ZP, Chen F, Dai Y, et al. Targeting truncated retinoid X receptor-alpha by CF31 induces TNF-alpha-dependent apoptosis. Cancer Res 2013;73:307-18.
16. Zhang H, Li L, Chen L, Hu L, Jiang H, Shen X. Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode. J Mol Biol 2011;407: 13-20.
17. Zhang H, Xu X, Chen L, Chen J, Hu L, Jiang H, et al. Molecular determinants of magnolol targeting both RXRalpha and PPARgamma. PLoS ONE 2011;6:e28253.
18. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
19. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013;12:147-68.
20. Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 2010;17:560-73.
21. Gao W, Liu J, Hu M, Huang M, Cai S, Zeng Z, et al. Regulation of proteolytic cleavage of retinoid X receptor-alpha by GSK-3beta. Carcinogenesis 2013; 34:1208-15.
22. Fathi AR, Krautheim A, Kaap S, Eger K, Steinfelder HJ. Michael adducts of ascorbic acid as inhibitors of protein phosphatase 2A and inducers of apoptosis. Bioorg Med Chem Lett 2000;10:1605-8.
23. Park J, Pei D. trans-Beta-nitrostyrene derivatives as slow-binding inhibitors of protein tyrosine phosphatases. Biochemistry 2004;43:15014-21.
24. Zhang XK, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, et al. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992;358:587-91.
25. Xie P. TRAF moleculesin cell signaling and in human diseases. J Mol Signal 2013;8:7.
26. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006;22:245-57.
27. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30: 689-700.
28. Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compoundsastherapeutic agents for a wide range of cancer types. PPAR Res 2008;2008:494161.
29. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, et al. Nitrolinoleic acid: anendogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A 2005;102:2340-5.
30. Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem 2005;280:42464-75.
31. Naoum F, Kasiotis KM, Magiatis P, Haroutounian SA. Synthesis of novel nitro-substituted triaryl pyrazole derivatives as potential estrogen receptor ligands. Molecules 2007;12:1259-73.
32. Le Guevel R, Oger F, Lecorgne A, Dudasova Z, Chevance S, Bondon A, et al. Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds. Bioorg Med Chem 2009; 17:7021-30.
33. Ferreira AM, Minarrieta L, Lamas Bervejillo M, Rubbo H. Nitro-fatty acids as novel electrophilic ligands for peroxisome proliferator-activated receptors. Free Radic Biol Med 2012;53:1654-63.
34. Kaap S, Quentin I, Tamiru D, Shaheen M, Eger K, Steinfelder HJ. Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds. Biochem Pharmacol 2003;65:603-10.
35. Wang WY, Hsieh PW, Wu YC, Wu CC. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol 2007; 74:601-11.
36. He Y, Varadarajan S, Munoz-Planillo R, Burberry A, Nakamura Y, Nunez G. 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem 2014;289:1142-50.
37. Li Y, Zhang J, Schopfer FJ, Martynowski D, Garcia-Barrio MT, Kovach A, et al. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol 2008;15:865-7.
38. Egea PF, Mitschler A, Moras D. Molecular recognition of agonist ligands by RXRs. Mol Endocrinol 2002;16:987-97.
39. le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, Balaguer P, et al. Activation of RXR-PPAR heterodimersbyorganotin environmental endocrine disruptors. EMBO Rep 2009;10:367-73.
40. Schopfer FJ, Cole MP, Groeger AL, Chen CS, Khoo NK, Woodcock SR, et al. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem 2010;285:12321-33.
41. Geisler AC, Rudolph TK. Nitroalkylation - a redox sensitive signaling pathway. Biochim Biophys Acta 2012;1820:777-84.
42. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol 2013;230:241-8.
43. Chu WM. Tumor necrosis factor. Cancer Lett 2013;328:222-5.